Last reviewed · How we verify
NCT05080842
A Study of AC682 for the Treatment of Locally Advanced or Metastatic ER+ Breast Cancer
Phase 1 trial testing AC682 in Breast Cancer in 21 participants. Terminated before completion.
4 April 2024
Quick facts
| Lead sponsor | Accutar Biotechnology Inc |
|---|---|
| Phase | Phase 1 |
| Status | Terminated |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 21 |
| Start date | 12 November 2021 |
| Primary completion | 4 April 2024 |
| Estimated completion | 4 April 2024 |
| Sites | 5 locations across United States |
Drugs / interventions tested
- AC682 — full drug profile →
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
Sponsor
Accutar Biotechnology Inc — full company profile →
Who can join
18 and older, any sex, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This clinical trial is evaluating a drug called AC682 in participants with estrogen receptor positive/human epidermal growth factor 2 negative (ER+/HER2-) locally advanced or metastatic breast cancer. The main goals of this study are to: * Identify the recommended dose of AC682 that can be given safely to participants * To evaluate the side effects of AC682 * To evaluate pharmacokinetics of AC682 * To evaluate the effectiveness of AC682
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
PROTAC targeted protein degraders: the past is prologue.
Békés M, Langley DR, Crews CM. · · 2022 · cited 2098× · PMID 35042991 · DOI 10.1038/s41573-021-00371-6 -
Expanding PROTACtable genome universe of E3 ligases.
Liu Y, Yang J, Wang T, Luo M, et al · · 2023 · cited 117× · PMID 37845222 · DOI 10.1038/s41467-023-42233-2 -
Targeted protein degradation: advances in drug discovery and clinical practice.
Zhong G, Chang X, Xie W, Zhou X. · · 2024 · cited 112× · PMID 39500878 · DOI 10.1038/s41392-024-02004-x -
Next-generation selective estrogen receptor degraders and other novel endocrine therapies for management of metastatic hormone receptor-positive breast cancer: current and emerging role.
Lloyd MR, Wander SA, Hamilton E, Razavi P, et al · · 2022 · cited 72× · PMID 35923930 · DOI 10.1177/17588359221113694 -
Oral Selective Estrogen Receptor Degraders (SERDs) in Breast Cancer: Advances, Challenges, and Current Status.
Downton T, Zhou F, Segara D, Jeselsohn R, et al · · 2022 · cited 48× · PMID 36081610 · DOI 10.2147/dddt.s380925 -
Proteolysis-Targeting Chimeras (PROTACs) in Cancer Therapy: Present and Future.
Li R, Liu M, Yang Z, Li J, et al · · 2022 · cited 45× · PMID 36557960 · DOI 10.3390/molecules27248828 -
E3 ligase ligand optimization of Clinical PROTACs.
Jiang H, Xiong H, Gu SX, Wang M. · · 2023 · cited 35× · PMID 36733714 · DOI 10.3389/fchem.2023.1098331 -
Proteolysis-Targeting Chimera (PROTAC) Delivery into the Brain across the Blood-Brain Barrier.
Tashima T. · · 2023 · cited 31× · PMID 37489365 · DOI 10.3390/antib12030043
Verify or expand the search:
- PubMed search for NCT05080842
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of AC682
Trials testing the same drug.
- NCT05489679 — A Study of AC682 In Chinese Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer · Phase 1 · terminated
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other Accutar Biotechnology Inc trials
Trials by the same sponsor.
- NCT05780034 — A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies · Phase 1 · recruiting
- NCT05673109 — A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer · Phase 1 · terminated
- NCT05654532 — Study of AC699 in Patients With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) · Phase 1 · active not recruiting
- NCT05489679 — A Study of AC682 In Chinese Patients With ER+/HER2- Locally Advanced or Metastatic Breast Cancer · Phase 1 · terminated
- NCT05241613 — A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer · Phase 1 · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05080842 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Accutar Biotechnology Inc
- Last refreshed: 13 February 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05080842.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing